Clinical and histological features of lupus nephritis induced by anti-TNFα therapy

NDT Plus

Volumn 1, Issue 4, 2008, Pages 221-224

  Piccolo, Tiziana ^a,b   Lisi, Piero ^a   Valicenti, Enza ^a   Pannarale, Giovanni ^a   Coratelli, Pasquale ^a  

^a POLICLINICO   (Italy)

^b NONE   (Italy)

Author keywords

Anti tumour necrosis factor therapy; Lupus nephritis

Indexed keywords

ALBUMIN; AZATHIOPRINE; CALCIUM; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; ERYTHROPOIETIN; ETANERCEPT; HEMOGLOBIN; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UREA; VITAMIN D;

ADULT; ALBUMIN BLOOD LEVEL; ARTHRITIS; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LEUKOCYTE COUNT; LUPUS ERYTHEMATOSUS NEPHRITIS; PLASMAPHERESIS; PRIORITY JOURNAL; SEROLOGY; THROMBOCYTE COUNT; ULTRAFILTRATION; UREA BLOOD LEVEL; URINALYSIS; VITAMIN SUPPLEMENTATION;

EID: 48749087113     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfn060     Document Type: Article

References (10)

1. Ramos-Casals M, Brito-Zeron P, Munoz S et al. Autoimmune diseases induced by TNF-targeted therapies. Analysis of 233 cases. Medicine 2007; 86: 242-251
2. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-250
3. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT study group. Lancet 1999; 354: 1932-1939
4. Shakoor N, Michalska M, Harris CA et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359: 579-580
5. Haake H, Koneke J, Amann K et al. Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis. Med Klin 2007; 102: 852-857
6. Stokes MB, Foster K, Markowitz GS et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005; 20: 1400-1406
7. Mor A, Bingham CO III, Barisoni L et al. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol 2005; 32: 740-743
8. Charles PJ, Smeenk RJ, De Long J et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: Findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43: 2383-2390
9. Gordon C, Ranges GE, Greenspan JS et al. Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol 1989; 52: 421-434
10. Pisetsky DS. Tumour necrosis factor α blockers and the induction of anti-DNA autoantibodies. Arthritis Rheum 2000; 43: 2381-2382